According to the latest research by iData Research, many segments of the U.S. ENT market are relatively commoditized. As companies compete to gain market share in these segments, innovation is lacking.
Recently, there has been a trend in the U.S. where procedures are being more commonly performed in office settings. The increase in office procedures has led to an increase in the number of units sold, as physicians need to purchase the equipment required to perform the procedures. Because of the competition and increase in office procedures, we decided to list out some market developments throughout 2021 and 2022.
U.S. ENT MARKET DEVELOPMENTS
In April 2021, Olympus launched the H-SteriScopes™ single-use bronchoscopes. H-SteriScopes offer a wide range of diagnostic and therapeutic applications due to their enhanced functionality and premium features. As a result, procedures can be performed anywhere, at any time, with confidence.
In September 2021, Boston Scientific acquired Lumenis’ surgical division. As part of a distribution agreement, Boston Scientific already offered Lumenis urology lasers in the U.S. and Japan prior to the closing. As a result of this acquisition, Boston Scientific will now sell lasers and fibers – as well as otolaryngology lasers – across all geographies.
In November 2021, Karl Storz received FDA approval for its FIVE S® single-use scope. This flexible scope is equipped with an ergonomic handle, a long connection cable, and a 2.2-mm suction channel, among many other improved features.
In August 2022, Preceptis Medical got extended FDA clearance for its Hummingbird® Tympanostomy Tube System (TTS) for sales in the offices. Hummingbird TTS combines multiple tools and steps to provide a comprehensive ear tube procedure. The Hummingbird allows ENTs or otolaryngologists to perform ear tube insertion in the office in a single pass.
In August 2022, Acclarent received FDA Clearance of TruDi® Shaver Blade Designed for Navigated Accuracy During ENT Procedures. The TruDi® Shaver Blade interacts with all of TruDi®’s advanced navigation features including TruSeg™, which uses artificial intelligence to segment critical anatomical structures, such as the eyes and brain, which can then function as beacons to alert the surgeon when the navigated surgical device approaches the structure during ENT procedures.
U.S. ENT MARKET ANALYSIS AND FORECAST
According to iData’s upcoming 2023 ENT Market Report, the U.S. market is expected to reach a valuation around $1.6 billion by 2029. The full report suite on the U.S. market for ENT endoscopic and bronchoscopic devices includes ENT endoscopes, ENT powered instruments, ENT hand instruments, ENT surgical energy devices, balloon dilation devices, drug-eluting stents, bronchoscopes, bronchoscopic hand instruments, tracheobronchial stents, bronchoscopic biopsy devices and foreign body removal devices.
Our 2023 report includes metrics such as unit sales, average selling prices (ASPs), market values, market trends, a complete competitive analysis and COVID-19 analysis, along with market drivers, market limiters, and more.
If you want to request a pre-publication summary for the 2023 U.S. ENT Market, feel free to request below: